- Home
- TXMD vs INAB Comparison
TXMD vs INAB Comparison
Compare TXMD & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | INAB |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 22.9M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TXMD | INAB |
|---|---|---|
| Price | $2.23 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $180.00 |
| AVG Volume (30 Days) | 33.0K | ★ 35.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.61 | 43.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | $427.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $90.64 | ★ N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.72 | $0.12 |
| 52 Week High | $2.95 | $4.20 |
Technical Indicators
Market Signals| Indicator | TXMD | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 45.87 |
| Support Level | $1.05 | $1.52 |
| Resistance Level | $2.54 | $2.55 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 40.91 | 47.37 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.